Use of cell proliferation data in cancer risk assessment: FDA view.
The possible uses of cell proliferation data in cancer risk assessment can be divided into three categories: direct use of mathematical models that incorporate rates of cell proliferation, use of experimental data on secondary mechanisms produced by cell proliferation, and using studies of cellular growth rates to extend the dose range of bioassay data. These three approaches are briefly discussed and some indication of their potential application to cancer risk assessment is outlined.
Office of Toxicological Sciences, Food and Drug Administration, Washington, DC 20204.
R J
RJ
Scheuplein
D000818:Animals; D015197:Carcinogenicity Tests; D002273:Carcinogens / Q000633:toxicity; D002455:Cell Division; D006801:Humans; D008433:Mathematics; D008954:Models, Biological; D009369:Neoplasms / Q000209:etiology* / Q000473:pathology; D012307:Risk Factors; D012377:Rodentia; D014481:United States; D014486:United States Food and Drug Administration
D002273:Carcinogens